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Abstract
Apoptosis depends upon the activation of intracellular caspases which are classically induced by either an intrinsic
(mitochondrial based) or extrinsic (cytokine) pathway. However, in the process of explaining how endotoxin activated
monocytes are able to induce apoptosis of vascular smooth muscle cells when co-cultured, we uncovered a transcellular
apoptosis inducing pathway that utilizes caspase-1 containing microvesicles. Endotoxin stimulated monocytes induce the
cell death of VSMCs but this activity is found in 100,000 g pellets of cell free supernatants of these monocytes. This activity is
not a direct effect of endotoxin, and is inhibited by the caspase-1 inhibitor YVADcmk but not by inhibitors of Fas-L, IL-1b
and IL-18. Importantly, the apoptosis inducing activity co-purifies with 100 nm sized microvesicles as determined by TEM of
the pellets. These microvesicles contain caspase-1 and caspase-1 encapsulation is required since disruption of
microvesicular integrity destroys the apoptotic activity but not the caspase-1 enzymatic activity. Thus, monocytes are
capable of delivering a cell death message which depends upon the release of microvesicles containing functional caspase-
1. This transcellular apoptosis induction pathway describes a novel pathway for inflammation induced programmed cell
death.
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Introduction
Caspase-1 was first described as the IL-1 converting enzyme
responsible for processing and hence activating proIL-1b to its
active form [1–3]. However, its structural homology to C. elegans
death genes prompted the discovery of a class of proteases now
termed caspases [4,5]. It is now recognized that caspase-1
regulation depends upon the assembly of a protein complex,
now termed the inflammasome. This structure is centered upon
the adapter molecule ASC and typically another member of the
NOD-like receptor or RIG-I receptor family that is thought to
provide an intracellular danger sensing function [6–8]. Sensing of
danger signals, either from pathogens (pathogen associated
molecular patterns, PAMPs), from exogenous agents like silica,
or endogenous signals such as ATP and uric acid, induces
inflammasome assembly [6]. This assembly autoactivates caspase-
1 by a proximity mediated process with the resultant release from
the cell of processed IL-1b and IL-18 [9–12]. Interestingly, it is
now generally recognized that with caspase-1 activation, not only
is IL-1b and IL-18 processed and released by these danger sensing
macrophages, but many of the inflammasome components
themselves are also released, notably caspase-1 and ASC [13].
Although caspase-1 is generally categorized as an ‘‘inflamma-
tory’’ caspase by virtue of its activation of IL-1b and IL-18, it is
now clear that caspase-1 also plays a role in certain forms of cell
death, e.g. sepsis induced lymphocyte apoptosis [14] and bacterial
induced pyroptosis [15–17]. In these caspase-1 mediated process-
es, the dying cell’s endogenous caspase-1 serves as the executioner
caspase. However, in the process of analyzing how monocytes
induce cell death in a co-culture model, we uncovered a novel
transcellular mechanism of caspase-1 mediated cell death.
Monocytes sensing of danger signals induces the release of IL-
1b, caspase-1 and ASC. These molecules are released in
microvesicle packets that have the capacity to deliver a cell death
message to proliferating smooth muscle cells. This cell death
message is dependent upon the catalytic function of caspase-1 and
upon the integrity of the microvesicle capsules. This novel pathway
of caspase-1 mediated cell death adds a novel twist to the
characterized functions of caspase-1.
Results
Contact independent apoptosis of vascular smooth
muscle cells by monocytes
Since monocytes take up residence with vascular smooth muscle
cells (VSMCs) in atherosclerotic plaques [18–21], we used an in
vitro co-culture model to analyze the monocyte ability to induce
VSMC death. Vascular smooth muscle cells (VSMC) were
cocultured with monocytes in the presence or absence of LPS
(1 mg/ml) for 24 h. Monocytes stimulated with LPS induced
significant VSMC cell death, as compared to VSMC cocultured
with control unstimulated monocytes (Figure 1A). To determine
whether this cell death induction of VSMC by monocytes was
contact dependent, VSMC were cultured with conditioned
medium from monocytes untreated or pretreated with LPS for
2 h. Cell survival was measured using crystal violet staining, total
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activation assays. Conditioned medium from LPS treated
monocytes resulted in significant VSMC cell death, whereas
conditioned medium from control monocytes had no effect
(Table 1, Top panel). Cell death was confirmed to be apoptosis
as measured by classical apoptotic morphology of cells under light
microscope (Figure 1C), Annexin V and caspase-3 activation
assays (Figure 1A and B ). Apoptosis induction by monocytes was
completely inhibited in the presence of the specific caspase-1
inhibitor, YVADcmk. Briefly, monocytes were pretreated with
YVADcmk for 15 min, washed and then stimulated with LPS or
left untreated for 2 h. Conditioned medium was then added to
VSMC and effect on apoptosis was analyzed. YVADcmk
completely abrogated apoptosis induced by LPS stimulated
monocytes (Figure 1).
Cytokines and active caspase-1 release by LPS-stimulated
monocytes
Conditioned medium from monocytes was analyzed for the
presence of IL-1b and IL-18 by ELISA. Upon stimulation with
LPS, monocytes released both mature IL-1b and IL-18 into the
supernatant. IL-18 was measured in the medium as early as
15 min after LPS challenge. IL-1 b became detectable at 1 h and
reached a peak at 2–3 h (Figure 1D). Release of both mature IL-
18 and IL-1 b was completely abrogated in the presence of the
caspase-1 inhibitor, YVADcmk. Caspase-1 was also identified in
the supernatants of stimulated monocytes. Active caspase-1 was
released as early as 15 min from LPS stimulated monocytes and
this release increased in a time dependent manner (Figure 1E).
That the released caspase-1 from LPS stimulated cells was active
was confirmed by both immunoblot and WEHDafc enzymatic
assay (Figure 1E).
Microvesicular release of active caspase-1 and ASC by
LPS-stimulated monocytes
We next examined the mode of release of active caspase-1 from
stimulated monocytes freshly isolated from buffy coats. Micro-
vesicle shedding is a recognized mode of cytokine release, as
described for IL-1b and Fas ligand [22–29]. To examine the
possibility of microparticle/microvesicle release microvesicles
were isolated from unstimulated and LPS challenged fresh
monocytes by ultracentrifugation. Isolated microvesicles were
then quantified by flow cytometry. Stimulated monocyte
microvesicles were enriched for smaller vesicles (i.e. ,0.2 mm),
50.4% versus 9.3% for unstimulated monocyte microvesicles
(Figure 2A and Table 2). Isolated microvesicles were also
characterized by transmission electron microscopy. The LPS
induced microvesicles were less than 0.1 micron (Figure 2B)b y
comparison to calibrated beads. That this microvesicle release by
monocytes upon stimulation by LPS was not the effect of
monocyte cell death was confirmed by analyzing the stimulated
Figure 1. VSMC apoptosis by monocytes is contact indepen-
dent and inhibited by caspase-1 inhibitor. Monocytes were
stimulated with LPS (1 mg/ml) for 15 min in the presence or absence of
YVADcmk. VSMCs were either co-cultured with these monocytes or
subjected to conditioned medium from the stimulated monocytes.
Apoptosis was measured by A) Annexin/PI and B) caspase-3 assays
along with C) morphology. D) Monocytes were also stimulated with
LPS (1 mg/ml) for indicated time and IL-18 and IL-1b release was
measured from supernatants by ELISA. E) Supernatants were also
analyzed for total and functional caspase-1 using ELISA and WEHD-
assays. Cytokine and enzymatic assays depicted in graphs are based on
average of n=2 experiments.
doi:10.1371/journal.pone.0007140.g001
Table 1. Induction of VSMC death.
Experiment Samples
Absorbance
(570 nm) P values
LPS stimulated Control 0.8960.13
monocyte supernatant LPS 0.4560.08 0.0004*
Monocyte microvesicles Control 0.8360.13
(pretreatment) LPS + DMSO 0.3860.05 0.003*
LPS + YVAD 0.8560.03 0.630*, 0.0001
#
VSMC (pretreatment) Control 0.3260.03
YVAD 0.5860.03 0.018*
DEVD 0.7860.05 0.010*
ZVAD 0.8960.02 0.003*
Monocyte microvesicles Control 0.8760.09
(posttreatment) Intact 0.4360.05 0.004*
Homogenized 0.8560.04 0.86*, 0.013@
Heat Inactivated 0.7960.01 0.186*, 0.007
$
ˆCell death of VSMC was measured at 18 h after treatments as outlined.
Monocyte supernatants or MVs were all generated by 15 min. incubations with
LPS (1 mg/ml). Vascular smooth muscle cell death was inversely related to the
crystal violet staining of resident cells as measured at A570. Top Panel, VSMC
death by conditioned medium from LPS stimulated monocytes (*LPS vs
control); Second Panel, Inhibition of VSMC death by MV isolated from LPS
treated monocytes that had been pretreated with the caspase-1 inhibitor, YVAD
(*Treatments vs control,
#YVAD vs LPS); Third Panel, VSMCs were pretreated
with different inhibitors for 30 mins before being subjected to MV (*Inhibitors
vs control); Bottom Panel, Effect of homogenization or heat-inactivation of
MV before addition to VSMC (* Different MVs vs control,
@homogenized vs
intact,
$heat inactivated vs intact).
doi:10.1371/journal.pone.0007140.t001
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measurements from the supernatants (Table 3). These micro-
vesicles were then subjected to immunoblot analysis for the
presence of caspase-1 and ASC. Active microvesicular caspase-1
was shed from monocytes stimulated with LPS in a time
dependant manner, as early as 15 min after LPS stimulation
(Figure 2C). This release of active caspase-1 in vesicles
correlated with our earlier observation of active caspase-1 in the
supernatants of monocytes stimulated for 15 min. That caspase-1
released in the vesicle was active was also confirmed by WEHDafc
assay of the vesicles (Figure 2C). Caspase-1 release in MVs was
Figure 2. Active caspase-1 release from stimulated monocytes occurs in microvesicles. Monocytes were stimulated with LPS (1 mg/ml) for
15 min. Microvesicles were isolated from LPS stimulated monocytes supernatant by ultracentrifugation. Isolated microvesicles were analyzed by A)
flow cytometry and B) transmission electron microscopy. C) Microvesicles were further analyzed for presence of catalytically active caspase-1 and
inflammasome protein, ASC, by immunoblot. Activity of caspase-1 was also measured using WEHD-enzymatic assay. Immunoblots are representative
of n=3 experiments and caspase-1 enzymatic assay is average of n=2 experiments.
doi:10.1371/journal.pone.0007140.g002
Table 2. Monocyte microvesicle quantitation by flow
cytometry.
Samples % Total
,0.2 .0.2–,1.0
Unstimulated MV 9 20
12 17
81 9
Stimulated MV 50 12
58 12
48 18
ˆEvents were quantified for 10,000 flow events of vesicles both ,0.2 and .0.2–
,1.0 microns from monocytes either untreated or stimulated with LPS (1 mg/
ml) for 15 minutes. Data from n=3 experiments.
doi:10.1371/journal.pone.0007140.t002
Table 3. Microvesicle release by stimulated monocytes is
independent of cell death.
Time (h)
Annexin-V assay
(% positive cells)
LDH assay
(% cytotoxicity)
00 0
0.25 4 362
0.5 4 361
ˆMonocytes were analyzed for cell death after stimulation with LPS for different
periodsoftime.Annexin V assay (n=2 experiments)andLDH(n=3experiments).
doi:10.1371/journal.pone.0007140.t003
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the amounts of caspase-1 in the cells. Approximately 15% of
caspase-1 was released by the monocytes packaged in microves-
icles as early as 15 min after LPS stimulation (Table 4).
Monocytes pretreated with caspase-1 inhibitor, YVADcmk also
released caspase-1 in vesicles upon stimulation, but in an inactive-
proform. Microvesicles also contained the inflammasome protein
ASC, critical for caspase-1 activation. ASC, similar to caspase-1,
was identified both in the supernatants and microvesicles from
LPS stimulated monocytes (Figure 2C).
Monocyte microvesicular caspase-1 induces VSMC
apoptosis
Vascular smooth muscle cells were then co-cultured with
microvesicles isolated from conditioned medium of either unstimu-
lated monocytes or monocytes stimulated with LPS for different
periods of time. Monocytes used in all experiments were freshly
isolated from buffy coats. Cell death of VSMCs was analyzed using
Annexin V and crystal violet assays. Microvesicles isolated from as
early as 15 min of LPS stimulation to monocytes induced
approximately 43% cell death of VSMC as compared to control
vesicles (Table 5, Panel 1 and 2). Active caspase-1 was
encapsulated in the microvesicles as observed by WEHD assay
(Table 5, Panel 3). Increased caspase-3 activity was also observed
in VSMCs upon cell death induction (Table 5, Panel 4).
To test the involvement of encapsulated caspase-1 in vesicles in
VSMC cell death induction, MVs were isolated from monocytes
either pretreated or not with caspase-1 inhibitor, YVADcmk prior
to LPS challenge for 15 min. Increased cell death of VSMC
(approximately 40%) was observed as compared to vesicles from
unstimulated monocytes (Figure 3A). Vesicles from monocytes
pretreated with YVADcmk before LPS challenge were unable to
induce death of VSMC (Figure 3B and Table 1, Second
panel), suggesting the possible role of caspase-1 or its substrate in
the induction of VSMC cell death. The non-vesicular fractions did
not induce killing of the smooth muscle cells (Figure 3C). To
further investigate the possibility of caspase-1 and other caspase
involvement in this cell death induction, VSMCs were pretreated
with YVAD (caspase-1 inhibitor), DEVD (caspase-3 inhibitor) and
ZVAD (pan-caspase inhibitor) before being subjected to MVs
isolated from monocytes stimulated with LPS for 15 min. Cell
death was measured after 18 h. All caspase inhibitors were capable
of inhibiting induction of VSMC cell death. YVAD abrogated
approximately 50% of cell death induced by MVs, whereas
DEVD and ZVAD prevented 70% and 90% respectively
(Figure 3D and Table 1, Third panel).
To test if the LPS–induced monocyte-specific killing of smooth
muscle cells was directly due to the exogenous caspase-1, as
opposed to its products, we used blocking reagents to common
cytokines released by monocytes upon LPS challenge (IL-18 and
IL-1b) as well as Fas ligand to then monitor VSMC killing. Briefly,
monocytes were pretreated with specific caspase-1 inhibitor
(YVADcmk) or DMSO for 30 min. Monocytes were then washed
with PBS to remove the remaining inhibitor. VSMC cells were
also pretreated with IL-1 receptor antagonist (IL-1RA), IL-18
binding protein (IL-18BP), soluble Fas ligand or saline (as control)
for 30 min. Monocytes were then stimulated with LPS for 15 min
and microvesicles were isolated from the conditioned medium.
Pretreated VSMCs were then subjected to these microvesicles (as
described earlier) and analyzed for cell death. VSMC death was
abrogated only by pretreatment with the specific caspase-1
inhibitor, YVADcmk. Inhibiting IL-18, IL-1b or FAS did not
significantly affect the killing of VSMC, as compared to saline
control (Figure 4A). We also performed experiments stimulating
vascular smooth muscle cells with LPS, rIL-18, IL-1b or soluble
FasL directly for 24 h. Direct stimulation of smooth muscle cells
with these stimuli did not induce VSMC apoptosis.
Table 4. Quantification of caspase-1 release in microvesicles.
Time Cell lysate (CE) Microvesicles (MV)
(h) (ng/10
7cells) (ng/10
7cells)
03 0 1 60.1
0.25 33615 63
0.5 40612 460.7
14 2 613 460.4
24 3 618 462
ˆMonocytes (10
7/ml) were stimulated with LPS for indicated time and MVs were
isolated from the supernatant. Cell lysates (CE) and MVs isolated from the
supernatant were quantified for caspase-1 using ELISA.
doi:10.1371/journal.pone.0007140.t004
Table 5. Time course of VSMC cell death by MV.
Time Annexin-V assay CV assay Casp-1 activity in MV Casp-3 activity in MV
(h) (%positive cells) (% cell death (AFU/mg) (AFU/mg)
07 1 60.9 0 0.2
0.25 42 40631 1 . 6 4 . 6
0.5 50 48641 6 . 8 7 . 8
15 4 5 3 63 17.3 16.1
26 0 5 8 68 10.0 12.8
46 5 6 2 64 23.4 15.2
66 1 6 4 63 18.4 16.3
12 57 6563 14.5 12.1
24 54 5863 9.4 8.3
ˆMonocytes were stimulated with LPS for indicated period of time and microvesicles (MV) were isolated. MVs were then subjected to VSMC and analyzed for cell death
using Annexin-V assay (Panel 1) and Crystal violet (CV) assay (Panel 2). Caspase-1 activity (Panel 3) and caspase-3 activity (Panel 4) were measured from MVs and
VSMCs respectively. Annexin-V and caspase -1 and 3 assays represented here are average of N=2 experiments. CV assay is representative of N=4 experiments.
doi:10.1371/journal.pone.0007140.t005
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exogenous active caspase-1 in inducing smooth muscle death,
plasmids expressing EGFP tagged pro-caspase-1 (both cysteine
wildtype and mutant) were expressed in HEK293 cells along
with the inflammasome protein ASC. ASC is capable of
activating the wild type caspase-1 but not the cysteine active site
mutant of caspase-1. Expression patterns of wild type and mutant
caspase-1 as well as ASC in HEK293 cells were confirmed by
immunoblot. Activity of caspase-1 upon transfection was also
confirmed by enzymatic assay and immunoblotting (data not
shown). Smooth muscle cells were then cultured in conditioned
medium from both active and mutant caspase-1 transfected cells.
Conditioned medium containing wildtype active caspase-1 was
capable of inducing apoptosis but the mutant form was not,
confirming the specific role of active caspase-1 in inducing cell
death (Figure 4B).
This novel role of caspase-1 was further confirmed by using a
THP-1 derived cell free system. Cell free extracts from THP-1
cells were incubated either at 4uCo r3 0 uCf o r1ha n dt h e n
subjected to centrifugation at 10,000xg following the caspase-1
activation protocol of Dubyak et al [30]. Active caspase-1 was
identified only in the lipid layer of the cell free extract after
incubation at 30uC( Figure 4C). Activity was also confirmed
using WEHD-afc cleavage (Figure 4D). The lipid layer
exhibited a significant amount of caspase-1 activity when
compared to non-lipid fractions. When smooth muscle cells were
incubated with either the lipid or non-lipid extract of THP-1
Figure 3. Microvesicles released by LPS- stimulated monocytes
induce VSMC apoptosis. Monocytes were stimulated with LPS (1 mg/
ml) for 15 min and microvesicles were isolated from supernatant by
ultracentrifugation. VSMCs were then treated with microvesicles
isolated from unstimulated, LPS, and LPS + YVAD treated monocytes.
Cell death was measured by Annexin V/PI assays using flow cytometry.
A) Representative data of apoptosis of VSMC by flow cytometry using
Annexin V/PI assay. B) Average of quantitative analysis of the same
(n=2); C) VSMCs were pretreated with specific caspase inhibitors, YVAD
(casp-1inhibitor), DEVD (casp-3 inhibitor) and ZVAD (pan-caspase
inhibitor). MVs were isolated from monocytes stimulated with LPS for
15 min and subjected to the pretreated VSMCs for 18 h. Cell death was
analyzed by Annexin V/PI assays (n=2); D) Monocytes were again
stimulated with LPS (1 mg/ml) for 15 min and both microvesicles (MV)
and the non-vesicular fractions (non-MV) were isolated from superna-
tant of monocytes using ultracentrifugation. Both microvesicle (MV) and
non-microvesicle (non-MV) fractions were subjected to VSMC and
apoptosis was analyzed using Annexin V/PI assays.
doi:10.1371/journal.pone.0007140.g003
Figure 4. Microvesicle encapsulated exogenous caspase-1
directly induces VSMC apoptosis. A) Monocytes were either
pretreated with YVAD-cmk or DMSO for 30 min. Cells were then rinsed
with PBS and then stimulated with LPS (1 mg/ml) for 15 min.
Microvesicles were isolated from the conditioned medium. Additionally,
VSMCs were also pretreated with either saline, or with IL-1RA, IL-18 bp
or sFAS for 30 min (* indicates VSMC pretreatments). VSMCs were then
subjected to the isolated microvesicles from LPS stimulated monocytes.
(&) VSMC+ MV from control monocytes; ( ) VSMC+ MV from LPS/
YVAD monocytes; ( ) VSMC treated with IL-1RA+ MV from LPS treated
monocytes; (%) VSMC treated with IL-18 bp + MV from LPS treated
monocytes; ( ) VSMC treated with sFAS+ MV from LPS treated
monocytes. Apoptosis of VSMC was measured using Annexin V/PI assay.
Graph represents average of n=2 experiments. B) HEK-293 cells were
transfected with either wild type or mutant caspase-1 (0.2 mg) along
with ASC (0.2 mg) using Lipofectamine 2000. Transfection was
normalized using vector controls. Supernatants were collected from
the transfected cells and subjected to VSMC. Apoptosis was measured
using Annexin V/PI assays. THP-1 cells were lysed and cell lysates were
either kept at 4uC or incubated at 30uC for 1 h. Cell lysates were then
centrifuged at 15,000 X g for 20 min. Both lipid and non-lipid fractions
were measured for caspase-1 activity using C) immunoblot and D)
WEHD-enzymatic assay. E) Both fractions were also subjected to VSMC
and cell death was analyzed by Annexin V/PI assays.
doi:10.1371/journal.pone.0007140.g004
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having active caspase-1 induced smooth muscle cell apoptosis
(Figure 4E).
Encapsulation is necessary for exogenous caspase-1
induced cell death
Finally, we examined the role of encapsulation in the cell death
induced by exogenous caspase-1. Since caspase-1 release from
stimulated monocytes was contained in microvesicles, we asked
whether this encapsulation was critical for the cell death induction.
To test this hypothesis, microvesicles derived from LPS stimulated
monocytes (as described previously) were either kept intact or
subjected to disruption (15 strokes on ice) or heat-inactivation
(incubated at 65uC for 10 min). VSMCs were then cocultured
with these vesicles and analyzed for cell death by Annexin V and
crystal violet assays. Intact microvesicles from LPS stimulated
monocytes induced significant VSMC cell death (,50% as
compared to cells exposed to vesicles shed by unstimulated
monocytes by Annexin V assay) (Figure 5A). The crystal violet
assay demonstrated a similar trend of cell death; VSMCs treated
with intact microvesicles exhibited approximately 50% cell death
as compared to 2–10% by homogenized and heat inactivated
microvesicle treatments (Table 1, Bottom panel). In contrast,
cell death was completely abrogated in cells exposed to both
ruptured and heat-inactivated microvesicles. Intact, homogenized
and heat-inactivated microvesicles were then analyzed for caspase-
1 activity using both immunoblot and enzymatic assay systems.
Both intact and homogenized microvesicles contained active
caspase-1, whereas the caspase-1 activity was completely lost by
heat-inactivation of microvesicles (Figure 5B).
Discussion
Executioner caspases such as caspases 3, 6 and 7 are recognized
mediators of apoptotic cell death [4,31–33], whereas caspase-1 is
the prime member of the inflammatory caspase family which
functions to activate proIL-1b and proIL-18. Nevertheless,
caspase-1 clearly can contribute to cell death as has been
described for macrophages responding to intracellular pathogens
in pyroptosis [14–17] and as we have shown for splenic B
lymphocyte apoptosis in response to sepsis [14]. However, that
caspase-1 might be released from one cell to induce the cell death
of a bystander cell has not been previously described. It is in this
context that we here describe a novel pathway of caspase-1
mediated cell death. Monocytes induced by endotoxin are capable
of releasing caspase-1 encapsulated in microvesicles that has the
capacity to target an external cell, in this case proliferating
vascular smooth muscle cells, for programmed cell death.
VSMC apoptosis occurs in all stages of atherosclerosis and is
triggered by a combination of factors and conditions [18–21].
Because monocytes are the key inflammatory cells present in
atherosclerotic plaques, we hypothesized that monocytes might
provide the stimulus for VSMC apoptosis. We reasoned that this
apoptotic event may be a critical component of atherosclerotic
plaque rupture. We therefore developed an in vitro model of
VSMC monocyte interactions to study potential mechanisms of
the apoptotic event. Our findings document for the first time the
novel role of monocyte-derived, microvesicular caspase-1 in the
induction of VSMC apoptosis. Whereas monocytes cocultured
with VSMC induced no significant cell death, remarkable VSMC
death was induced by LPS treatment of the cocultures or when
VSMCs were cocultured with conditioned medium from mono-
cytes stimulated with LPS. Importantly, LPS in the absence of
monocytes did not induce VSMC death. This apoptosis was
completely abrogated when monocytes were pretreated with a
specific caspase-1 inhibitor, YVADcmk.
Since it is generally believed that caspase-1’s apoptotic function
involves an enzymatic cleavage of cytosolic substrates, we
wondered whether the cell death inducing activity from monocytes
was packaged in vesicles. That is, encapsulation of caspase-1
would provide a means for both protecting the caspase-1 prior to
cytosolic delivery and allowing its entry into the cytosol of targeted
cells. Our findings support the concept that monocytes release
microvesicles which carry active caspase-1 into the cytosol of
targeted smooth muscle cells and induce apoptosis. We believe
that our studies are the first to test this hypothesis.
Microvesicles have been known to be shed by cells during
activation or apoptosis and to carry different factors and proteins.
Monocyte/macrophage derived MVs have been reported to
transport biologically significant amounts of phosphatidylserine
and tissue factor [23–25,34,35]. Of note, monocyte/macrophage
derived MVs have been found in human atherosclerotic lesions
[23,34,36]. Furthermore, caspase-1 has also been reported to be
enhanced in the plaque regions associated with an increase in
infiltration of monocytes and macrophages [36].
Whether this encapsulation of active caspase-1 is important in
the actual events related to plaque rupture remain to be shown.
Figure 5. Vesiculation is necessary for exogenous caspase-1
mediated apoptosis of VSMC. Monocytes were either stimulated
with LPS (1 mg/ml) for 15 min, 30 min, 1 h and 2 h or left untreated
prior to microvesicles isolation. Microvesicles were then either kept
intact or disrupted by mild homogenization or subjected to heat
inactivation of encapsulated caspase-1. A) Microvesicles isolated from
different times of LPS stimulation were then subjected to VSMC for 18 h
and induction of apoptosis of VSMC was analyzed by Annexin V/PI
assay. B) Caspase-1 activity of each fraction was measured using WEHD
enzymatic assay. Time (h) in the figure indicates time of LPS stimulation
of monocytes prior to MV isolation.
doi:10.1371/journal.pone.0007140.g005
Microvesicular Caspase-1
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packaging of exogenous caspase-1 into microvesicles. These
particles have the potential to contribute to smooth muscle cell
death in plaques. Interestingly, the release of caspase-1 in vesicles
parallels what we know about the release of the caspase-1
substrates IL-1b and IL-18. IL-1b release has been hypothesized
to occur in the form of small packages termed microvesicles or
vesicular bodies [26–29]. It is therefore, reasonable to hypothesize
that caspase-1 release from cells might also require vesiculation. In
this context, the present study confirms that active caspase-1 is
released by activated monocytes in microparticles less than 0.1 mm
and that this encapsulation is critical for its apoptotic function.
Support for the need for caspase-1 encapsulation derives from our
finding that mechanical disruption of microvesicles completely
abrogates their apoptotic potential.
Members of the caspase-related protease family have been
shown to play an important role in apoptosis [4,14–17,37–40].
However the specific role of caspase-1 in apoptosis is controversial.
Caspase-1 knockout animals are born healthy without detectable
morphological abnormalities, whereas caspase-3 deficient animals
have major birth defects, particularly neurological defects which
imply a role for caspase-3 in developmental apoptosis [39,40].
Furthermore, we have previously documented that spontaneous
monocyte apoptosis is not dependent upon caspase-1 but upon
caspase-3 activity [41]. On the other hand, over expression of
caspase-1, in a rat fibroblast cell line, induces an apoptosis which is
blocked by crmA, a cow pox virus protein that inhibits caspase-1
[42]. The involvement of caspase-1 in neuronal cell apoptosis is
also well established. Gagliardini et al, 1994, observed the ability of
a caspase-1 inhibitor to prevent apoptosis induced by nerve growth
factor deprivation [43]. Furthermore, caspase-1 has been impli-
cated in the death of Salmonella infected dendritic cells and
monocyte derived macrophages [43]. Work from our own
laboratory has shown the unique role of caspase-1 in regulating
sepsis survival by regulating lymphocyte apoptosis [14,44]. Thus,
the present work lends support to the notion that caspase-1 is
important in at least selected forms of programmed cell death. Our
findings suggest that caspase-1 directly regulates the apoptosis of
smooth muscle cells and that encapsulation of this active caspae-1
in microvesicles is critical for its function.
Other potential mechanisms to explain the VSCM apoptosis by
the monocyte product include the concomitant release of potent
cytokines. Caspase-1 is known to be principally responsible for the
production of mature IL-1b and IL-18 from their precursor forms.
These inflammatory cytokines have been linked to organ injury
and failure [14,44,45]. However, in this context, we found no
statistical difference between apoptosis of smooth muscle cells that
were subjected to conditioned medium after blockade of both IL-
1b and IL-18.
Lastly, and perhaps linked to the apoptosis concept, is the
possibility that caspase-1 has important effects on the host
intracellulardefense system. This idea is supported by the growing
body of evidence that places caspase-1 at the center of complex of
regulatory proteins termed the inflammasome [6,46]. It is
believed that caspase-1 interacts with various members of these
novel molecules via its caspase recruitment domain or CARD
[6–8]. It is likely that caspase-1 may play a central role in the
structural integrity, organization and/or regulation of these
intracellular protein complexes. For example, caspase-1 is known
to interact with RIP2, a kinase that is important in upstream
activation of NF-kB, via CARDs on both molecules [47,48]. We
have recently demonstrated that caspase-1 may also function as a
scaffolding molecule that promotes RIP2 mediated NF-kB
activation [47].
In summary, our results demonstrate that caspase-1 plays a
central role in the regulation of apoptosis. This novel apoptotic
event is dependent upon encapsulation of exogenous caspase-1
into released microvesicles that allow targeting of the active
enzyme to the cytosol of different cells, in this study vascular
smooth muscle cells. Future studies will need to determine whether
this mechanism is targeted to specific cells or acts via a
concentration dependent stochastic process.
Materials and Methods
Reagents
Bacterial lipopolysaccharide (LPS), Escherichia coli strain
0127:B8, Westphal preparation, was obtained from Difco (Detroit,
MI). RPMI 1640 and phosphate buffered saline (PBS) was
purchased from BioWhitaker (Walkersville, MD), and fetal bovine
serum (FBS) was obtained from Hyclone (Logan, UT). The pan-
caspase inhibitor, z-Val-Ala-Asp (O-Methyl) fluoromethyl ketone
(zVADfmk) and inactive caspase inhibitor, z-Phe-Ala-fluoro-
methylketone (zFAfmk) were purchased from Enzyme Systems,
(Irvine, CA). All other reagents were obtained from Sigma-Aldrich
(St. Louis, MO) unless otherwise specified.
PBMC isolation and culture conditions
Human peripheral blood monocytes were isolated from the
heparinized blood of normal donor or buffy coats from the
American Red Cross. Normal donor blood samples were obtained
after informed written consent as approved by the Ohio State
Institutional Review Board. Details provided in online supple-
ment. Isolated monocytes were cultured in a 5-ml polypropylene
tube at 10610
6 cells/ml in RPMI1640 supplemented with 10%
fetal bovine serum (FBS) at 37uC in humidified incubator.
Typically, cells were stimulated with LPS (1 mg/ml) for indicated
time and the cell pellet separated from supernatant by centrifu-
gation at 3000 X g for 5 min.
Vascular smooth muscle cell culture
Vascular smooth muscle cells (VSMCs) (passage 3 to 7) were
obtained from Clonetics (Biowhitaker, Inc, Walkersville, MD)
from human heart donors. VSMC identity was initially confirmed
by a-smooth muscle actin staining. VSMC initially were grown in
growth medium (SmGM2; Clonetics) with 5% FBS, and at 60–
70% cell confluence, the media was changed to serum-free
medium (50:50 of DMEM/F12 media with 5 ml of ITS, PSA, L-
glutamine, and nonessential amino acids per 500 ml of solution).
VSMC were co-cultured with either monocytes or conditioned
medium from monocytes as per further experiments. Co-culture
experiments were performed with RPMI1640 in 10% FBS
throughout the experiments.
Cell death assays
VSMC cells were seeded in cell culture plates at a density of
60–70% confluency of cells/well. After overnight incubation with
monocytes, conditioned medium or microvesicles from condi-
tioned medium in the presence or absence of inhibitors, VSMC
were subjected to cell death analysis. Cell death was identified
using light microscopy, Annexin V, caspase-3 activation [49] and
crystal violet and LDH assays, as described in details in
supplement information (Appendix S1).
Microvesicle isolation and identification
Microvesicles were isolated from conditioned medium using
ultracentrifugation as described in SI. Isolated microvesicles were
Microvesicular Caspase-1
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microscopy.
ELISAs
Cytokine levels of IL-1b and IL-18, as well as caspase-1 levels
were measured by sandwich enzyme linked immunoassay (ELISA)
(details in Appendix S1).
Caspase-1 activity
For caspase-1 activity assay, monocytes were isolated from buffy
coats and cultured at a concentration of 10610
6 cells/150 mli n
96-well plates. Cells were then stimulated with LPS (5 mg/ml) and
supernatants were collected from each well. Cells were spun at
1000g64uC for 10 min to collect the supernatant. Supernatants
were then subjected to caspase-1 ELISA or enzymatic assay
[49–51]. Assay details in supplement section (Appendix S1).
In-vitro caspase-1 activation
In-vitro caspase-1 activation was performed using THP-1 cells
as described by in Appendix S1.
Expression plasmids, cell culture and transfection
Caspase-1, ASC plasmids were either created or obtained as
gifts. Inhibitors of caspase-1 were purchased. HEK293 cells were
cultured and used for transfection of these plasmids. See details in
Appendix S1.
Statistical analysis
Data are represented as the mean 6 standard error of the mean
(SEM) from at least three independent experiments. All other
simple comparisons were performed with Student’s t test, with
p,0.05 considered to represent statistical significance.
Supporting Information
Appendix S1
Found at: doi:10.1371/journal.pone.0007140.s001 (0.04 MB
DOC)
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